Current adoptive immunotherapy (AIT) requires cumbersome cell culture to generate adequate numbers of lymphocytes. The applicant has described a novel technique, namely stimulation of lymphocytes with bryostatin 1 and a calcium ionophore (B/1), which leads to the rapid expansion of tumor-sensitized T cells that have therapeutic activity in vivo. This has been translated to a Phase I clinical trial. To determine whether pharmacologic activation of T lymphocytes can be used to amplify weak immune responses and induce regression of weakly immunogenic tumors, without the need for prolonged cell culture, the applicant will determine: a) whether T cells activated only briefly in vitro with B/I mediate regression of very weakly immunogenic 4T1 mammary tumors; b) whether the anti-tumor effects of cytokines are involved in the anti-tumor effects of these drugs; c) whether Bryo, AS101, and/or IL-2 augment each other's anti-tumor effects; d) whether Bryo and AS101 augment the effect of gene-modified vaccines to induce protective immunity; and e) whether this approach can cause regression of established tumors. To understand the mechanisms underlying the efficacy of Bryo-activated T cells, the applicant will determine whether B/I selectively activates memory T cells, perhaps as a result of different patterns of protein kinase C expression and/or activation, and whether activation of DLN cells will preferentially expand certain TcR families compared to the starting population. To determine whether B/I-activated T lymphocytes from DLN of patients with breast cancer respond to a relevant tumor antigen, the applicant will test the following hypotheses: a) B/I-activated T cells from breast cancer patients respond to HER-2/neu-derived epitopes presented by HLA-A2; b) DLN cells are more likely to manifest responses to HER-2/neu than are peripheral blood lymphocytes from the same patients; c) T cell reactivity to HER-2/neu will be less likely or weaker in patients with metastases to the lymph nodes; and d) the responses of breast cancer patients' T cells to HER-2/neu are related to over-expression of HER-2/neu by their tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA048075-12
Application #
6172161
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Hecht, Toby T
Project Start
1988-08-15
Project End
2002-02-28
Budget Start
2000-06-01
Budget End
2002-02-28
Support Year
12
Fiscal Year
2000
Total Cost
$244,928
Indirect Cost
Name
Virginia Commonwealth University
Department
Surgery
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Miller, Catriona H T; Graham, Laura; Bear, Harry D (2010) Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol 11:54
Chin, Cynthia S; Miller, Catriona H T; Graham, Laura et al. (2004) Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol 16:1283-94
Parviz, Maryam; Chin, Cynthia S; Graham, Laura J et al. (2003) Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52:739-50
Chin, Cynthia S; Bear, Harry D (2002) Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity. Ann Surg Oncol 9:94-103
Chin, C S; Graham, L J; Hamad, G G et al. (2001) Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J Surg Res 98:108-15
Kos, F J; Cornell, D L; Lipke, A B et al. (2000) Protective role of IL-2 during activation of T cells with bryostatin 1. Int J Immunopharmacol 22:645-52
Kos, F J; Bear, H D (1998) Involvement of protein kinase C-delta in CD28-triggered cytotoxicity mediated by a human leukaemic cell line YT. Immunology 94:575-9
Baldwin, N G; Rice, C D; Tuttle, T M et al. (1997) Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. J Neurooncol 32:19-28
Rice, C D; Baldwin, N G; Biron, R T et al. (1997) Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes. J Neurooncol 32:29-38
Merchant, R E; Baldwin, N G; Rice, C D et al. (1997) Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res 19:145-52

Showing the most recent 10 out of 31 publications